Tofacitinib ameliorates skin inflammation in a patient with severe autosomal recessive congenital ichthyosis
Clinical and Experimental Dermatology · 19.07.2024 · 49 (8) · 887-892
DOI: 10.1093/ced/llae080 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 12.03.2024. Verfasst von Yu-Chen Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: International Center for Wound Repair, Regeneration at National Cheng Kung University, National Cheng Kung University Hospital.
Abstract (Originalsprache)
Autosomal recessive congenital ichthyosis (ARCI) is a genetically heterogeneous disorder with aberrant skin scaling and increased transepidermal water loss (TEWL). Current treatments for ARCI are limited and suboptimal. We present the case of a 27-year-old man with ARCI resulting from a homozygous missense variant in TGM1. RNA-sequencing of lesional skin revealed aberrant Janus kinase–signal transducer and activator of transcription signalling, providing a rationale for innovative treatment with a Janus kinase inhibitor. We prescribed oral tofacitinib (11 mg daily) for 26 weeks. Rapid improvements in erythema and fissuring occurred within the first month. Sustained reductions in 5-D itch scale and Dermatology Life Quality Index scores were also observed. TEWL decreased for the first 10 weeks but increased thereafter. Tofacitinib downregulated inflammatory genes and pathways, while enhancing skin barrier markers. Moreover, transglutaminase 1 distribution was normalized although enzymatic activity remained deficient. This study suggests that oral tofacitinib may be a useful therapy to consider for patients with ARCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- International Center for Wound Repair and Regeneration, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Cellular Biochemistry Laboratory, Graduate School of Pharmaceutical Sciences, Nagoya University, Nagoya, Japan.
- Department of Dermatology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
- St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.
ORCID-Profile: Masashi Akiyama, John A McGrath, Chao-Kai Hsu
Förderung
- International Center for Wound Repair
- Regeneration at National Cheng Kung University
- National Cheng Kung University Hospital
Zitieren
APA
Lin, Y. C., Hong, Y. K., Aala, W. J. F., Hitomi, K., Akiyama, M., McGrath, J. A., & Hsu, C. K. (2024). Tofacitinib ameliorates skin inflammation in a patient with severe autosomal recessive congenital ichthyosis. Clinical and Experimental Dermatology, 49(8), 887-892. https://doi.org/10.1093/ced/llae080
Vancouver
Lin YC, Hong YK, Aala WJF, Hitomi K, Akiyama M, McGrath JA, et al. Tofacitinib ameliorates skin inflammation in a patient with severe autosomal recessive congenital ichthyosis. Clinical and Experimental Dermatology. 2024;49(8):887-892. doi:10.1093/ced/llae080
BibTeX
@article{Lin2024,
author = {Lin, Yu-Chen and Hong, Yi-Kai and Aala, Wilson Jr F and Hitomi, Kiyotaka and Akiyama, Masashi and McGrath, John A and Hsu, Chao-Kai},
title = {Tofacitinib ameliorates skin inflammation in a patient with severe autosomal recessive congenital ichthyosis},
journal = {Clinical and Experimental Dermatology},
year = {2024},
volume = {49},
number = {8},
pages = {887--892},
doi = {10.1093/ced/llae080}
}
EUVIMED